ACM
NKTR icon

Acrisure Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Acrisure Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,652
Closed -$17.4K – 165
2023
Q1 		$17.4K Sell
1,652
-3,157
-66% -$95.5K 0.02% 251
2022
Q4 		$163K Buy
+4,809
New +$233K 0.18% 211

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acrisure Capital Management's NKTR Position: Q2 2023 in Review

Acrisure Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 1,652 shares — an estimated $17.4K sold.

Acrisure Capital Management first reported a position in NKTR in Q4 2022 and held it in 2 quarters. The position peaked at $163K in Q4 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Acrisure Capital Management reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 1,652 Nektar Therapeutics shares in Q2 2023, an estimated $17.4K.
  • Acrisure Capital Management first reported a position in Nektar Therapeutics in Q4 2022 and held it in 2 quarters.
  • Acrisure Capital Management's Nektar Therapeutics position peaked at $163K in Q4 2022.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Acrisure Capital Management's 13F filing for Q2 2023.